{
}
Roche is emphasizing the advantages of fixed-duration dosing for its bispecific therapies, Lunsumio and Columvi, in the competitive landscape against AbbVie/Genmab’s Epkinly for B-cell lymphomas. The outcome of ongoing Phase III studies may significantly influence market positioning.Meanwhile, Ken Mulvany has returned to lead BenevolentAI through a restructuring aimed at refocusing on its core strengths and plans to delist from Euronext Amsterdam. In another setback, Cervomed's shares plummeted nearly 80% after its lead product, neflamapimodin, failed in a Phase IIb trial for Lewy body dementia, raising questions among investors about the trial's shortcomings.
Roche's subcutaneous Lunsumio has shown comparable efficacy to its intravenous version in treating follicular lymphoma, with an overall response rate of 76.6% versus 81.1% for IV. The new formulation offers advantages in administration time and safety, with lower rates of adverse events and cytokine release syndrome. Roche is also advancing its bispecific therapies, including trials for Lunsumio in combination with other treatments for diffuse large B-cell lymphoma.
Robert F. Kennedy Jr.'s appointment as Health Minister in Donald Trump's administration has triggered a significant decline in pharmaceutical stocks across the US and Europe, with fears of potential drug price caps impacting investor confidence. Major companies like UCB and argenx saw sharp drops, reflecting broader concerns about the future of drug pricing and regulation under Kennedy's leadership. Analysts suggest that while there are constraints on his power, the potential for reduced regulations could lead to increased mergers and acquisitions in the sector.
Genmab A/S
Companies
| Symbol | GMAB |
| Name | Genmab A/S |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | Denmark |
| State | |
| City | Copenhagen |
| Zipcode | 1560 |
| Website | http://www.genmab.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Roche emphasizes fixed-duration dosing in bispecifics competition for B-cell lymphomas
17:07 12.12.2024
Roche advances subcutaneous Lunsumio in lymphoma amid competitive CAR-T landscape
21:16 09.12.2024
healthcare sector reacts negatively to robert f kennedy jr appointment
United States Dollar
Moderna, Inc.
BioNTech SE
Pfizer Inc.
Genmab A/S
Novavax, Inc.
UCB SA
AstraZeneca PLC
Sanofi
GSK plc
USA
CHE
BEL
Robert F. Kennedy Jr.
Donald Trump
Ashish Jha
James Capretta
Chris Meekins
Show more
15:24 15.11.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Supply Chain Management
Government Economic Policies
Workplace Trends
Industry Mergers & Acquisitions
Stock Market Updates
Fintech Startups
Venture Capital Investments
Financial Scams and Security
Finance Mergers & Acquisitions
CEO Changes
Cryptocurrency Trends
Emerging Startups
Cryptocurrency & Blockchain Regulations
Funding Rounds & Investments
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Google Inc.
Alphabet Inc.
NVIDIA Corporation
Tesla, Inc.
Microsoft Corporation
Amazon.com, Inc.
Delhivery Limited
Ecom Express Ltd.
Foxconn Technology Co., Ltd.
Samsung SDI Co., Ltd.
SWIGGY LIMITED
UWS JP Morgan EM A OSB
Netflix, Inc.
Airbnb, Inc.
Adobe Inc.
GEELY AUTO
TENCENT
CarTrade Tech Limited
Concrete Credit Limited
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
South Korean Won
Algerian Dinar
Vietnamese Đồng
Indonesian Rupiah
Australian Dollar
Egyptian Pound
Saudi Riyal
Swiss Franc
British Pound Sterling
Russian Ruble
Pakistani Rupee
People: